ENGOT-ov66/GEICO/AVB500-OC-004/ARRAVIVE A phase 3, randomized, double-blind, adaptive, placebo/Paclitaxel-controlled study of AVB-S6-500 in combination with Paclitaxel in patients with Platinum-resistant recurrent ovarian cancer (active, recruiting)
ENGOT-ov56/NSGO-CTU/DOVACC A three-arm randomized study of olaparib, durvalumab and UV1 as maintenance therapy in BRCAwt patients in with relapsed ovarian cancer where platatinum combination therapy is an option (active, recruiting)
ENGOT-ov51/MITO/NItCHE Randomized phase III trial on Niraparib-TSR 042 vs TSR 042 vs physician’s choice chemotherapy in recurrent ovarian, fallopian tube or primary peritoneal cancer patients not candidate for further platinum treatment (active, recruiting)
ENGOT-ov45/NCRI/ATHENA ATHENA – A multicenter, randomized, double-blind, placebo-controlled phase 3 study in ovarian cancer patients evaluating Rucaparib and Nivolumab as maintenance treatment following response to front-line Platinum-based chemotherapy (active, recruiting)
FIRST (3000-03-005/ENGOT-OV44) A patient Centric Randomized Phase 3 Comparison of Standard of Care Platinum Based Therapy to the Same Plus TSR-042 As FIRST Line Treatment of Patients with Stage III or IV Non-Mucinous Ovarian Cancer (active, not recruiting)
MITO-16b – MANGO-OV2b – ENGOT-ov 17 Platinum-Sensitive A multicenter phase III randomized study with second line chemotherapy plus or minus Bevacizumab in patients with platinumsensitive epithelial ovarian cancer recurrence after a Bevacizumab/Chemotherapy first line (active, not recruiting)
ENDOMETRIAL
ENGOT-en12/NOGGO/INCYTE An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (POD1UM-204) (active, recruiting)
ENGOT-en11/BGOG/KEYNOTE-B21 A Phase 3, Randomized, Double-Blind Study of Pembrolizumab versus Placebo in Combination With Adjuvant Chemotherapy With or Without (Chemo)Radiotherapy for the Treatment of Newly Diagnosed High-Risk Endometrial Carcinoma After Surgery With Curative Intent (active, recruiting)
D9311C00001 / ENGOT-EN10 / DUO-E A Randomised, Multicentre, Double-blind, Placebo-controlled, Phase III Study of First-line Carboplatin and Paclitaxel in Combination with Durvalumab, Followed by Maintenance Durvalumab with or without Olaparib in Patients with Newly Diagnosed Advanced or Recurrent Endometrial Cancer (DUO-E) (active, recruiting)
KCP-330-024/ENGOT-EN5 – SIENDO A Randomized, Double-Blind, Phase 3 Trial of Maintenance with Selinexor/ Placebo After Combination Chemotherapy for Patients with Advanced or Recurrent Endometrial Cancer (active, not recruiting)
CERVICAL
ENGOT-cx17/GINECO/BRAVA Anti-PD-L1 Balstilimab vs Investigator Choice Chemotherapy in Patients with Recurrent Cervical Cancer (active, recruiting)
ENGOT-cx11/MITO/LACC A randomized, phase 3, double-blind study of chemoradiotherapy with or without pembrolizumab for the treatment of high-risk, locally advanced cervical cancer (active, recruiting)
R2810-ONC-1676 (EMPOWER) An open-label, randomized, phase 3 clinical trial of REGN2810 versus therapy of investigator’s choice chemotherapy in recurrent or metastatic platinum-refractory cervical carcinoma (Active, not recruiting)
BIG PARTICIPATION
CLINICAL STUDIES
Clinical and biological characterisation of Male Breast Cancer: An International EORTC, BIG, TBCRC and NABCG intergroup study. (Active, not recruiting)
GORTEC PARTICIPATION
CLINICAL TRIALS
A phase III randomized trial of post-operative adjuvant nivolumab and concomitant chemo-radiotherapy in high-risk patients with resected squamous cell carcinoma of head and neck (SCCHN) (Active, recruiting)
MEDICOVER PARTICIPATION
CLINICAL TRIALS
INNOVATE/1221/0002: New Minimal Residual Disease Detection Liquid Biopsy Test
WHO- ICRC
CLINICAL TRIALS
Mutographs of cancer: discovering the causes of cancer through mutational signatures
